

| First author | Year | Publication type | No. randomised | Clinical condition(s) | Age | % -female | Interventions | |
|-----------------|------|------------------|----------------|---|------|-----------|---------------|-----------------|
| | | | | | | | Experimental | Control |
| Abdel-Hady | 2011 | Abstract | 100 | Heart failure, EF<35% | NR | NR | Ivabradine | Placebo |
| Abdel-Salam | 2015 | Paper | 43 | Dilated cardiomyopathy, EF<40% | 50.8 | 46.5 | Ivabradine | Placebo |
| Adamyan | 2010 | Abstract | 118 | Heart failure, EF>50% | 58.0 | 24.8 | Ivabradine | No intervention |
| Adamyan | 2008 | Abstract | 145 | Heart failure, EF<35% | 58.0 | 30.0 | Ivabradine | No intervention |
| Adamyan | 2015 | Abstract | 104 | Heart failure, EF>50% | 63.2 | NR | Ivabradine | No intervention |
| Al Saadi | 2013 | Abstract | NR | Stable ischemic heart failure | NR | NR | Ivabradine | No intervention |
| AROUTUNOV | 2008 | Abstract | 24 | Decompensated heart failure | NR | NR | Ivabradine | No intervention |
| Babushkina | 2020 | Article | 109 | Heart failure, EF>50% | 57.7 | 37 | Ivabradine | No intervention |
| Bansal | 2019 | Abstract | 309 | Stable ischemic heart failure | NR | NR | Ivabradine | No intervention |
| Barilla | 2016 | Paper | 58 | Acute myocardial infarction, cardiogenic shock | 55.4 | 32.8 | Ivabradine | No intervention |
| Bi | 2020 | Paper | 198 | Heart failure | 56.8 | 46.0 | Ivabradine | No intervention |
| Cao | 2019 | Paper | 82 | Heart failure, EF<35% | 69.3 | 50.0 | Ivabradine | No intervention |
| Cavosoglu | 2015 | Paper | 58 | Decompensated heart failure, EF<35% | 65.6 | 25.7 | Ivabradine | No intervention |
| Chaudhari | 2014 | Abstract | 158 | Ischemic heart failure | NR | NR | Ivabradine | No intervention |
| Chen | 2020 | Paper | 60 | Chronic heart failure | 62.5 | 35 | Ivabradine | No intervention |
| Chen | 2021 | Paper | 100 | Chronic heart failure | 57.8 | 42 | Ivabradine | No intervention |
| Chen HX | 2021 | Paper | 60 | Severe chronic heart failure | 70.5 | 45 | Ivabradine | No intervention |
| Cheng | 2017 | Paper | 90 | Heart failure, EF<45% | 71.0 | 44.4 | Ivabradine | No intervention |
| Chumburidze | 2013 | Abstract | 30 | Dilated cardiomyopathy EF<35% | 54.0 | NR | Ivabradine | Placebo |
| Cong | 2018 | Paper | 90 | Heart failure | 64.6 | 60.0 | Ivabradine | No intervention |
| Deng | 2017 | Paper | 82 | Heart failure | 61.8 | 40.2 | Ivabradine | No intervention |
| Di | 2020 | Paper | 126 | Heart failure, EF<40%, HR>70 | 66.4 | 43.4 | Ivabradine | No intervention |
| Fox (BEAUTIFUL) | 2008 | Paper | 10917 | Stable coronary artery disease, heart failure, EF<40% | 65.2 | 17.1 | Ivabradine | Placebo |
| Fu | 2021 | Paper | 64 | Chronic heart failure, EF 40-50%, HR>70 | NR | NR | Ivabradine | No intervention |
| Gou | 2017 | Paper | 60 | Decompensated heart failure, EF<40% | 63.7 | 48.3 | Ivabradine | No intervention |
| Guo | 2017 | Paper | 32 | Heart failure, EF<40% | NR | 0.0 | Ivabradine | No intervention |
| He | 2019 | Paper | 68 | Coronary artery disease, heart failure, EF 40-49% | 64.8 | 47.1 | Ivabradine | No intervention |
| Hu | 2017 | Paper | 60 | Heart failure, EF<35% | 68.0 | 45.0 | Ivabradine | No intervention |
| Hu | 2018 | Paper | 169 | Acute myocardial infarction, heart failure | 63.0 | 3.6 | Ivabradine | No intervention |
| Huang J | 2017 | Paper | 102 | Heart failure | 71.5 | 41.2 | Ivabradine | No intervention |
| Komajda (EDIFY) | 2017 | Paper | 179 | Heart failure, EF>45% | 72.5 | 64.8 | Ivabradine | Placebo |

| | | | | | | | | |
|---------------|------|----------|-----|--|------|------|------------|-----------------|
| Kosmala | 2013 | Paper | 61 | Heart failure, EF >50% | 67.3 | 82.0 | Ivabradine | Placebo |
| Li | 2018 | Paper | 89 | Heart failure | 57.5 | 47.2 | Ivabradine | No intervention |
| Li B | 2020 | Paper | 110 | Chronic heart failure, HR>100 | 64.2 | 35.4 | Ivabradine | No intervention |
| Li Q | 2020 | Paper | 96 | Chronic heart failure, EF<50%, HR>75 | 65.3 | 33.6 | Ivabradine | No intervention |
| Liu | 2019 | Paper | 96 | Heart failure | 63.8 | 51.0 | Ivabradine | No intervention |
| Liu | 2020 | Paper | 98 | Heart failure | 67.4 | 60.2 | Ivabradine | Placebo |
| Liu Y | 2020 | Paper | 122 | Heart failure, EF>50%, HR>70 | 65 | 34.4 | Ivabradine | No intervention |
| Lofrano-Alves | 2016 | Paper | 26 | Heart failure, EF<40% | 42.0 | 46.2 | Ivabradine | Placebo |
| Lu | 2019 | Thesis | 60 | Dilated cardiomyopathy, EF<40% | 47.2 | 43.3 | Ivabradine | No intervention |
| Lu | 2020 | Paper | 70 | Chronic heart failure, EF 30-50% | 69.9 | 34.3 | Ivabradine | No intervention |
| Luo | 2021 | Paper | 120 | Heart failure, HR>70 | 84.2 | 42.5 | Ivabradine | No intervention |
| Ma | 2016 | Thesis | 60 | Heart failure, EF<40% | NR | NR | Ivabradine | Placebo |
| Ma | 2020 | Paper | 86 | Heart failure | 58.1 | 41.9 | Ivabradine | Placebo |
| Mansour | 2011 | Paper | 53 | Dilated cardiomyopathy, EF<40% | 49.0 | 40.0 | Ivabradine | No intervention |
| Manz | 2003 | Paper | 44 | Cardiomyopathy, EF 20-50% | 59.9 | NR | Ivabradine | Placebo |
| Mao | 2018 | Paper | 60 | Heart failure | 53.1 | 31.7 | Ivabradine | No intervention |
| Masi de Luca | 2018 | Abstract | 111 | Heart failure, EF>50% | 61.0 | 30.0 | Ivabradine | Placebo |
| Moiseev | 2011 | Abstract | 49 | Heart failure, EF<40% | 63.0 | 18.4 | Ivabradine | No intervention |
| Nguyen | 2018 | Paper | 19 | Planned CABG, EF 20-40% | 57.5 | 15.8 | Ivabradine | Placebo |
| Ordu | 2015 | Paper | 98 | Heart failure, EF<35% | 65.8 | 66.3 | Ivabradine | No intervention |
| Pal | 2015 | Paper | 22 | Heart failure, EF>50% | 74.6 | 65.0 | Ivabradine | Placebo |
| Pan | 2020 | Paper | 50 | Decompensated heart failure, EF<40% | 60.1 | 44.0 | Ivabradine | No intervention |
| Potapenko | 2011 | Paper | 49 | Systolic, chronic heart failure | 63.1 | 18.4 | Ivabradine | No intervention |
| Qi | 2019 | Paper | 96 | Heart failure | 59.7 | 45.8 | Ivabradine | No intervention |
| Raja | 2017 | Paper | 125 | Dilated cardiomyopathy, EF<40% | 47.2 | 43.1 | Ivabradine | No intervention |
| Sallam | 2016 | Paper | 100 | Coronary artery disease, heart failure, EF<40% | 63.5 | 30.0 | Ivabradine | No intervention |
| Sarullo | 2010 | Paper | 60 | Stable, ischemic heart failure, EF<40% | 52.7 | 25.0 | Ivabradine | Placebo |
| Shen | 2018 | Paper | 112 | Heart failure | 70.0 | 41.1 | Ivabradine | No intervention |
| Sisakian | 2015 | Paper | 54 | Heart failure, EF<40% | 59.9 | 18.5 | Ivabradine | No intervention |
| Song | 2021 | Paper | 96 | Heart failure | 69.4 | 43.8 | Ivabradine | No intervention |
| Su | 2020 | Paper | 70 | Heart failure | 69.0 | 44.3 | Ivabradine | No intervention |
| Su D | 2020 | Paper | 60 | Chronic heart failure, EF<50% | 61.8 | 48.3 | Ivabradine | No intervention |
| Sun | 2020 | Paper | 100 | Heart failure | 62.0 | 42.0 | Ivabradine | No intervention |

| | | | | | | | | |
|------------------|------|----------|------|--|------|------|------------|-----------------|
| Sun | 2021 | Paper | 118 | Chronic heart failure | 67.6 | 43.2 | Ivabradine | No intervention |
| Swedberg (SHIFT) | 2010 | Paper | 6558 | Heart failure, EF<35% | 60.4 | 23.4 | Ivabradine | Placebo |
| Tang | 2018 | Paper | 62 | Heart failure, EF<40% | 63.2 | 29.0 | Ivabradine | No intervention |
| Tarlovskaya | 2011 | Abstract | 18 | Heart failure, EF<35% | 53.5 | NR | Ivabradine | Placebo |
| Tatarchenko | 2008 | Paper | 59 | Coronary artery disease, heart failure, EF>45% | 57.3 | NR | Ivabradine | No intervention |
| Tsutsui | 2019 | Paper | 254 | Heart failure, EF<35% | 60.7 | 18.0 | Ivabradine | Placebo |
| Tsutsui | 2016 | Paper | 125 | Heart failure, EF<35% | 59.0 | 14.3 | Ivabradine | Placebo |
| Tumasyan | 2009 | Abstract | 126 | Severe heart failure | NR | NR | Ivabradine | No intervention |
| Tumasyan | 2012 | Abstract | 76 | Heart failure | 57.4 | NR | Ivabradine | No intervention |
| Tumasyan | 2016 | Abstract | 210 | Severe heart failure | 57.4 | NR | Ivabradine | No intervention |
| Tumasyan | 2017 | Abstract | 110 | Heart failure | 63.2 | NR | Ivabradine | No intervention |
| Tumasyan | 2018 | Abstract | 91 | Heart failure, mid range EF | 50.1 | NR | Ivabradine | No intervention |
| Vatinian | 2015 | Abstract | 52 | Coronary artery disease, heart failure, EF<35% | NR | NR | Ivabradine | No intervention |
| Wang | 2019 | Paper | 68 | Heart failure, EF <35% | 55.8 | 0.5 | Ivabradine | No intervention |
| Wang FC | 2017 | Paper | 96 | Heart failure | 70.6 | 43.8 | Ivabradine | No intervention |
| Wang JJ | 2017 | Paper | 40 | Heart failure | 52.9 | 55.0 | Ivabradine | No intervention |
| Wang Q | 2017 | Paper | 120 | Heart failure | 62.3 | 35.0 | Ivabradine | No intervention |
| Wang RM | 2017 | Paper | 78 | Heart failure | 59.9 | 28.3 | Ivabradine | No intervention |
| Wang YH | 2018 | Paper | 68 | Heart failure | 66.0 | 42.3 | Ivabradine | No intervention |
| Wang GK | 2020 | Paper | 72 | Chronic heart failure | 68.5 | 48.6 | Ivabradine | No intervention |
| Wang LJ | 2020 | Paper | 70 | Chronic heart failure | 57.0 | 22.9 | Ivabradine | No intervention |
| Wei | 2019 | Paper | 64 | Heart failure, EF<45% | 60.6 | 39.7 | Ivabradine | No intervention |
| Xia | 2016 | Paper | 78 | Heart failure | 60.7 | 44.9 | Ivabradine | No intervention |
| Xing | 2018 | Paper | 20 | Heart failure | 52.7 | 55.0 | Ivabradine | No intervention |
| Xu | 2019 | Paper | 77 | Heart failure, EF<50% | 68.1 | 0.5 | Ivabradine | No intervention |
| Xu | 2020 | Paper | 122 | Heart failure, EF<45% | 71.0 | 56.6 | Ivabradine | No intervention |
| Xue | 2020 | Paper | 90 | Chronic heart failure | 59.2 | 45.6 | Ivabradine | No intervention |
| Yang WT | 2019 | Paper | 80 | Heart failure, EF<45% | 62.2 | 0.4 | Ivabradine | No intervention |
| Yang Z | 2019 | Paper | 135 | Heart failure | 65.7 | 0.3 | Ivabradine | No intervention |
| Yao | 2016 | Paper | 72 | Heart failure, EF<40% | NR | NR | Ivabradine | No intervention |
| Yi | 2017 | Paper | 90 | Heart failure, EF<45% | 66.6 | 32.2 | Ivabradine | Placebo |
| Yu | 2019 | Paper | 66 | Dilated cardiomyopathy, EF<40% | 46.8 | 0.4 | Ivabradine | No intervention |
| Yu | 2018 | Paper | 86 | Heart failure | 62.5 | 43.0 | Ivabradine | No intervention |

| | | | | | | | | |
|----------|------|--------|-----|--|------|------|------------|-----------------|
| Yue | 2016 | Thesis | 80 | Heart failure, EF<40% | 68.3 | 50.0 | Ivabradine | No intervention |
| Zeng FC | 2019 | Paper | 65 | Heart failure | 72.0 | 0.6 | Ivabradine | No intervention |
| Zeng XM | 2019 | Paper | 90 | Heart failure | 70.6 | 0.5 | Ivabradine | No intervention |
| Zhang | 2018 | Paper | 60 | Coronary artery disease, heart failure | 64.2 | 48.3 | Ivabradine | No intervention |
| Zhang J | 2019 | Paper | 86 | Heart failure | 66.2 | 0.5 | Ivabradine | No intervention |
| Zhang XJ | 2019 | Paper | 110 | Heart failure | 61.6 | 0.4 | Ivabradine | No intervention |
| Zhang | 2020 | Paper | 85 | Coronary heart disease, heart failure | 64.4 | 0.4 | Ivabradine | No intervention |
| Zhang Y | 2020 | Paper | 54 | Chronic heart failure | NR | 51.9 | Ivabradine | No intervention |
| Zhang | 2021 | Paper | 94 | Chronic heart failure | 70.9 | 44.7 | Ivabradine | No intervention |
| Zhao | 2020 | Paper | 80 | Chronic heart failure | 68.3 | 46.3 | Ivabradine | No intervention |
| Zhou | 2019 | Thesis | 60 | Heart failure | 54.8 | 0.4 | Ivabradine | No intervention |
| Zhou | 2020 | Paper | 86 | Heart failure, EF<35%, HR>100 | 65 | 47.7 | Ivabradine | No intervention |